TPM-203 is under clinical development by Topas Therapeutics and currently in Phase I for Pemphigus Vulgaris. According to GlobalData, Phase I drugs for Pemphigus Vulgaris have a 91% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how TPM-203’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
TPM-203 overview
TPM203 is under development for the treatment of pemphigus vulgaris (orphan disease). It is administered through intravenous route of administration. The therapeutic candidates are developed based on nanoparticle technology which selectively targets liver sinusoidal endothelial cells (LSECs) and delivers peptides to such cells. The therapeutic candidates comprise of polymeric nanoparticle (NP) carrier for the selective delivery of autoantigen peptides to LSECs and is a mixture of four Topas Particle Conjugates (TPC0002, TPC0003,TPC0005 and TPC0012).
Topas Therapeutics overview
Topas Therapeutics is a biotechnological company that designs and develops nanoparticle products loaded with antigenic peptides. The company’s pre-clinical pipeline products are used in the treatment of allergies, immune mediated diseases, autoimmune diseases, and anti-drug-antibodies (ADA) induced conditions. It offers its unique approach to induce immune tolerance in blood borne antigens using liver sinusoidal endothelial cells (LSECs) to produce tolerogenic regulatory T cells (Tregs). Topas Therapeutics employs T cell-specific peptide antigen-loaded nanoparticles in proof-of-concept studies to treat immune-mediated diseases. The company’s therapeutic focus spans on the areas of neurology and immunology. Topas Therapeutics is headquartered in Hamburg, Germany.
For a complete picture of TPM-203’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
